Boston, MA (PRWEB) April 02, 2014
Cambridge Biomedical’s experience with bioanalytical assay development, optimization, validation and diagnostic testing has proved instrumental in assisting biotechnology and pharmaceutical companies that are focusing on therapies for orphan and ultra-rare disease in expediting their development programs.
Dr. John Reddington, COO of Cambridge Biomedical, commented that, “Our track record and experience with the needs of the orphan and ultra-rare disease drug development market, combined with our scientific expertise and wide range of technology platforms, has proven essential in reducing the time to market for this critical sector of the market. Throughout our organization we never forget that our primary mission is to support the ultimate end-user: the patient.”
Since 1997, Cambridge Biomedical has partnered with our clients by providing a diverse range of services from pre-clinical to post market. Including; assay development, optimization, validation and diagnostic testing. Conveniently located to support the Northeast pharmaceutical development market, yet with a national and global reach. Our personalized project management, approach along with a focus on delivering quality results and regulatory submission ready documentation and rapid turnaround times, ensure we meet our client’s product development timelines.